No Data
ZeJing Pharmaceutical - U (688266): The amount of losses continues to narrow down, with the realization of the pipeline under research accelerating.
This report is an overview: Product volume acceleration, significant reduction in losses. Intensive realization of research and development results, core pipeline accelerating into a harvest period. Early pipeline steadily advancing, expected to lead a new round of catalysis. Maintain a 'shareholding' rating. Investment Highlights: Maintain a 'shareholding'
Ze Jing Pharmaceuticals (688266): Research and development is progressing in an orderly manner.
Event: Recently, the company released the third quarter report of 2024. In Q3 2024, the company's total operating revenue was 0.143 billion yuan, a year-on-year increase of 130.67%, with a net income attributable to non-controlling interests of -32.1856 million yuan. ZG006
Zejiang Pharmaceuticals (688266): Revenue growth rate continues to increase month-on-month, showing advantages in the TCE field.
On October 25, 2024, Zejing Pharmaceuticals released its third quarter report for 2024, reporting a revenue of 0.384 billion yuan during the reporting period, a year-on-year increase of +36.16%; net income attributable to the parent company was -0.098 billion yuan, the same.
Zejing Pharmaceutical Report for the Third Quarter of 2024
Zejiang Pharmaceuticals (688266.SH) released its performance for the first three quarters, with a net loss of 97.903 million yuan.
Zejiang Pharmaceuticals (688266.SH) released the third quarter report for the first three quarters of 2024, during the reporting period the company achieved revenue...
Express News | Zejing Pharmaceutical: net income loss of 31.3669 million yuan in the third quarter.
No Data
No Data